Genetically modified t cells take on glioblastoma

NCT ID NCT06815432

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of immunotherapy for recurrent glioblastoma, an aggressive brain cancer. Researchers take a patient's own T cells and genetically engineer them to recognize and attack cancer cells that carry a protein called GPC3. The cells also include a safety switch that can be activated to stop them if needed. The study aims to find a safe dose and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GPC3-CAR T cells with IL15 and iCasp9 safety switch
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is an early Phase 1 trial with only 27 participants, focused on safety. The treatment may not shrink tumors or improve survival, and there are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain glioblastoma glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME OF BRAIN

Contacts and locations

Locations

Baylor St. Luke's Medical Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.